The estimated Net Worth of Carol Schafer is at least $3.44 Tysiąc dollars as of 23 June 2020. Ms. Schafer owns over 8,000 units of Idera Pharmaceuticals stock worth over $3,440 and over the last 6 years she sold IDRA stock worth over $0. In addition, she makes $0 as Independent Director at Idera Pharmaceuticals.
Carol has made over 2 trades of the Idera Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 8,000 units of IDRA stock worth $160,000 on 23 June 2020.
The largest trade she's ever made was buying 8,000 units of Idera Pharmaceuticals stock on 23 June 2020 worth over $160,000. On average, Carol trades about 371 units every 16 days since 2018. As of 23 June 2020 she still owns at least 8,000 units of Idera Pharmaceuticals stock.
You can see the complete history of Ms. Schafer stock trades at the bottom of the page.
Carol Anne Schafer serves as Independent Director of the Company. Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector. Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as a Managing Director at J.P. Morgan. Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University.
Carol Schafer is 56, she's been the Independent Director of Idera Pharmaceuticals since 2018. There are 12 older and 4 younger executives at Idera Pharmaceuticals. The oldest executive at Idera Pharmaceuticals, Inc. is Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., 67, who is the Scientific Advisor.
Carol's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... oraz Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: